On Tuesday morning 07/23/2024 the Abbott Laboratories share started trading at the price of $103.73.
Compared to the closing price on Monday 07/22/2024 on BTT of $103.72, this is a gain of 0.01%.
There are 1.74 B shares outstanding in Abbott Laboratories, which values the company at $177.18 B.
Is Abbott Laboratories stock a Buy, Sell or Hold?
Abbott Laboratories stock has received a consensus rating of buy. The average rating score is Aa3 and is based on 43 buy ratings, 6 hold ratings, and 0 sell ratings.What was the 52-week low for Abbott Laboratories stock?
The low in the last 52 weeks of Abbott Laboratories stock was 89.68. According to the current price, Abbott Laboratories is 115.80% away from the 52-week low.What was the 52-week high for Abbott Laboratories stock?
The high in the last 52 weeks of Abbott Laboratories stock was 121.68. According to the current price, Abbott Laboratories is 85.35% away from the 52-week high.What are analysts forecasts for Abbott Laboratories stock?
The 49 analysts offering price forecasts for Abbott Laboratories have a median target of 123.51, with a high estimate of 141.00 and a low estimate of 105.00. The median estimate represents a 84.08 difference from the last price of 103.85.Abbott Laboratories Stock Snapshot
103.86
Bid
10.00
Bid Size
103.90
Ask
37.00
Ask Size
7/23/2024
Date
9:52 AM
Time
26,459.00
Volume
103.72
Prev. Close
103.73
Open
177.51 B
Market Cap in USD
1.74 B
Number of Shares
103.48
Day Low
104.48
Day High
103.89
89.68
52 Week Low
121.68
52 Week High
103.89
2.08
Dividend in USD
1.89
Dividend Yield
33.77
P/E Ratio
99.28
Free Float in %
3.28
EPS in USD
22.26
Book Value per Share in USD
4.15
Cash Flow per Share in USD
Abbott Laboratories News More News
Historical Prices for Abbott Laboratories
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Abbott Laboratories Analyst Data
Total Analysts: 49
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 105.00
Median: 123.51
Highest: 141.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Abbott Laboratories Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/02/24 | Evercore | Maintained Buy | $120 | |||
| 06/04/24 | RBC Capital Markets | Maintained Buy | $125 | |||
| 05/30/24 | Goldman Sachs | Maintained Buy | $121 | |||
| 05/22/24 | Citigroup Corp. | Maintained Buy | $119 | |||
| 04/22/24 | Barclays Capital | Maintained Buy | $140 | |||
| 04/18/24 | RBC Capital Markets | Maintained Buy | $125 | |||
| 04/04/24 | Evercore | Maintained Buy | $125 | |||
| 04/03/24 | Citigroup Corp. | Maintained Buy | $128 | |||
| 02/14/24 | RBC Capital Markets | Maintained Buy | $128 | |||
| 01/26/24 | Barclays Capital | Maintained Buy | $141 | |||
| 01/25/24 | Citigroup Corp. | Maintained Buy | $126 | |||
| 01/25/24 | RBC Capital Markets | Maintained Buy | $128 | |||
| 01/25/24 | Raymond James Financial, Inc. | Maintained Buy | $127 | |||
| 01/11/24 | RBC Capital Markets | Maintained Buy | $128 | |||
| 01/03/24 | Raymond James Financial, Inc. | Maintained Buy | $124 | |||
| 12/13/23 | Wells Fargo & Co | Maintained Buy | $121 | |||
| 10/19/23 | Morgan Stanley | Maintained Hold | $107 | |||
| 10/19/23 | Wells Fargo & Co | Maintained Buy | $116 | |||
| 10/19/23 | Raymond James Financial, Inc. | Maintained Buy | $110 | |||
| 07/24/23 | Barclays Capital | Maintained Buy | $132 | |||
| 07/21/23 | Morgan Stanley | Maintained Hold | $112 | |||
| 07/21/23 | Mizuho | Maintained Hold | $115 | |||
| 07/21/23 | Wolfe Research | Upgraded to Hold | ||||
| 04/20/23 | UBS | Maintained Buy | $130 | |||
| 04/20/23 | Raymond James Financial, Inc. | Maintained Buy | $123 | |||
| 04/20/23 | Barclays Capital | Maintained Buy | $127 | |||
| 04/20/23 | Citigroup Corp. | Maintained Buy | $130 | |||
| 04/17/23 | BTIG Research | Maintained Buy | $130 | |||
| 04/17/23 | Raymond James Financial, Inc. | Maintained Buy | $116 | |||
| 04/10/23 | Wells Fargo & Co | Maintained Buy | $136 | |||
| 04/05/23 | Wells Fargo & Co | Maintained Buy | $136 | |||
| 03/29/23 | UBS | Maintained Buy | $117 | |||
| 01/27/23 | Barclays Capital | Maintained Buy | $125 | |||
| 01/26/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $125 | |||
| 01/26/23 | Raymond James Financial, Inc. | Maintained Buy | $123 | |||
| 01/26/23 | Bernstein | Maintained Buy | $132 | |||
| 01/24/23 | Mizuho | Maintained Hold | $110 | |||
| 01/06/23 | Morgan Stanley | Maintained Buy | $133 | |||
| 12/12/22 | Citigroup Corp. | Maintained Buy | $125 | |||
| 10/26/22 | Mizuho | Maintained Hold | $105 | |||
| 10/21/22 | Barclays Capital | Maintained Buy | $114 | |||
| 10/21/22 | Raymond James Financial, Inc. | Maintained Buy | $109 | |||
| 10/20/22 | Morgan Stanley | Maintained Buy | $117 | |||
| 10/20/22 | RBC Capital Markets | Maintained Buy | $126 | |||
| 10/18/22 | Barclays Capital | Maintained Buy | $118 | |||
| 10/17/22 | BTIG Research | Maintained Buy | $123 | |||
| 10/12/22 | Jefferies & Company Inc. | Maintained Hold | $110 | |||
| 10/11/22 | Morgan Stanley | Maintained Buy | $126 | |||
| 10/10/22 | Wells Fargo & Co | Maintained Buy | $140 | |||
| 07/27/22 | UBS | Maintained Buy | $128 |
Abbott Laboratories Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 41,746 | 44,821 | 48,204 | 51,480 | 55,005 |
| Dividend | 2.16 | 2.32 | 2.62 | 2.73 | - |
| Dividend Yield (in %) | 2.12 % | 2.28 % | 2.57 % | 2.67 % | - |
| EPS | 4.66 | 5.14 | 5.68 | 6.19 | 6.80 |
| P/E Ratio | 21.92 | 19.83 | 17.95 | 16.48 | 15.00 |
| EBIT | 9,334 | 10,396 | 11,504 | 12,587 | 13,743 |
| EBITDA | 10,721 | 11,714 | 13,002 | 13,656 | 14,182 |
| Net Profit | 8,161 | 8,992 | 9,912 | 10,818 | 11,850 |
| Net Profit Adjusted | 8,161 | 8,992 | 9,912 | 10,818 | 11,850 |
| Pre-Tax Profit | 9,611 | 10,602 | 11,680 | 12,763 | 13,942 |
| Net Profit (Adjusted) | 7,208 | 8,322 | 9,530 | 11,302 | - |
| EPS (Non-GAAP) ex. SOE | 4.64 | 5.25 | 5.75 | - | - |
| EPS (GAAP) | 3.41 | 3.94 | 4.60 | 5.30 | 5.51 |
| Gross Income | 23,471 | 25,424 | 27,538 | 29,581 | 31,851 |
| Cash Flow from Investing | -5,395 | -5,983 | -6,705 | - | - |
| Cash Flow from Operations | 11,029 | 10,626 | 11,477 | - | - |
| Cash Flow from Financing | -5,395 | -5,983 | -6,705 | - | - |
| Cash Flow per Share | 6.04 | 6.47 | 6.79 | - | - |
| Free Cash Flow | 9,314 | 8,819 | 9,271 | 10,449 | - |
| Free Cash Flow per Share | 5.73 | 5.94 | 6.31 | - | - |
| Book Value per Share | 23.23 | 24.14 | 25.62 | - | - |
| Net Debt | 4,695 | 540 | -3,292 | -13,655 | - |
| Research & Development Exp. | 2,661 | 2,830 | 3,022 | 3,109 | 3,344 |
| Capital Expenditure | 2,095 | 2,188 | 2,338 | 2,094 | - |
| Selling, General & Admin. Exp. | 11,487 | 12,231 | 13,069 | 13,885 | 14,764 |
| Shareholder’s Equity | 41,277 | 44,194 | 47,710 | - | - |
| Total Assets | 75,497 | 78,507 | 81,786 | - | - |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 21 | 21 | 23 | 23 |
| Average Estimate | - | 1.201 USD | 1.335 USD | 4.655 USD | 5.145 USD |
| Year Ago | - | 0.823 USD | 0.916 USD | 3.276 USD | - |
| Publish Date | - | 10/16/2024 | 1/22/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 18 | 18 | 22 | 22 |
| Average Estimate | - | 10,537 USD | 10,857 USD | 41,746 USD | 44,821 USD |
| Year Ago | - | 10,143 USD | 10,241 USD | 40,109 USD | - |
| Publish Date | - | 10/16/2024 | 1/22/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 40,109.00 | 43,653.00 | 43,075.00 | 34,608.00 | 31,904.00 | 30,578.00 | 27,390.00 |
| Change of sales in % | -8.12 | 1.34 | 24.47 | 8.48 | 4.34 | 11.64 | 31.35 |
| Gross profit on sales | 20,037.00 | 22,323.00 | 23,214.00 | 17,377.00 | 16,693.00 | 15,823.00 | 13,138.00 |
| Gross profit on sales change in % | -10.24 | -3.84 | 33.59 | 4.10 | 5.50 | 20.44 | 16.84 |
| Operating income | 6,435.00 | 8,362.00 | 9,200.00 | 5,291.00 | 4,591.00 | 3,844.00 | 2,136.00 |
| Operating income change in % | -23.04 | -9.11 | 73.88 | 15.25 | 19.43 | 79.96 | -34.26 |
| Income before tax | 6,664.00 | 8,306.00 | 8,211.00 | 4,968.00 | 4,077.00 | 2,873.00 | 2,231.00 |
| Income before tax change in % | -19.77 | 1.16 | 65.28 | 21.85 | 41.91 | 28.78 | 57.89 |
| Income after tax | 5,701.00 | 6,905.00 | 7,042.00 | 4,473.00 | 3,666.00 | 2,353.00 | 468.00 |
| Income after tax change in % | -17.44 | -1.95 | 57.43 | 22.01 | 55.80 | 402.78 | -66.01 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 34,387.00 | 37,533.00 | 39,172.00 | 39,545.00 | 36,586.00 | 36,451.00 | 45,152.00 |
| Long-term liabilities per share | 11.85 | 12.69 | 14.78 | 15.60 | 14.59 | 15.63 | 20.78 |
| Equity | 38,827.00 | 36,905.00 | 36,024.00 | 33,003.00 | 31,301.00 | 30,722.00 | 31,098.00 |
| Equity change in % | 5.23 | 2.47 | 9.21 | 5.46 | 1.85 | -1.21 | 50.44 |
| Balance sheet total | 73,214.00 | 74,438.00 | 75,196.00 | 72,548.00 | 67,887.00 | 67,173.00 | 76,250.00 |
| Balance sheet total change in % | -1.64 | -1.01 | 3.65 | 6.87 | 1.06 | -11.90 | 38.61 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 22.93 | 24.75 | 24.08 | 19.38 | 17.91 | 17.28 | 15.66 |
| P/E ratio (year end quote, basic EPS) | 33.77 | 28.05 | 35.75 | 43.72 | 42.20 | 54.41 | 213.27 |
| P/E ratio (year end quote, diluted EPS) | 33.77 | 28.05 | 35.75 | 43.72 | 42.20 | 54.41 | 213.27 |
| P/E ratio (year end quote) | 33.77 | 28.05 | 35.75 | 43.72 | 42.20 | 54.41 | 213.27 |
| Dividend yield in % | 1.89 | 1.75 | 1.29 | 1.40 | 1.52 | 1.60 | 1.88 |
| Equity ratio in % | 52.73 | 49.28 | 47.61 | 45.19 | 45.79 | 45.44 | 40.52 |
| Debt ratio in % | 46.97 | 50.42 | 52.09 | 54.51 | 53.89 | 54.26 | 59.22 |
Abbott Laboratories Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Morrone Louis H. | 06/30/2024 | 556.00 | 62,143.00 | 103.91 | Sell | No |
| Morrone Louis H. | 06/29/2024 | 269.00 | 62,699.00 | 103.91 | Sell | No |
| Earnhardt Lisa D | 05/06/2024 | 22,852.00 | 61,462.00 | 106.25 | Sell | No |
| McKinstry Nancy | 04/25/2024 | 1,866.00 | 37,089.00 | n/a | Buy | No |
| Roman Michael F | 04/25/2024 | 1,866.00 | 6,843.00 | n/a | Buy | No |
| Gonzalez Patricia Paola | 04/25/2024 | 1,866.00 | 5,284.00 | n/a | Buy | No |
| Kumbier Michelle | 04/25/2024 | 1,866.00 | 14,079.00 | n/a | Buy | No |
| STARKS DANIEL J | 04/25/2024 | 1,866.00 | 6,727,182.00 | n/a | Buy | No |
| Stratton John G | 04/25/2024 | 1,866.00 | 17,398.00 | n/a | Buy | No |
| Blount Sally E. | 04/25/2024 | 1,866.00 | 35,023.00 | n/a | Buy | No |
| O'Grady Michael | 04/25/2024 | 1,866.00 | 3,682.00 | n/a | Buy | No |
| Babineaux-Fontenot Claire | 04/25/2024 | 1,866.00 | 3,682.00 | n/a | Buy | No |
| McDew Darren W | 04/25/2024 | 1,866.00 | 8,757.00 | n/a | Buy | No |
| Alpern Robert J | 04/25/2024 | 1,866.00 | 39,163.00 | n/a | Buy | No |
| MCCOY JOHN A. JR. | 02/29/2024 | 472.00 | 18,760.00 | 118.50 | Sell | No |
| Morrone Louis H. | 02/29/2024 | 801.00 | 62,968.00 | 118.50 | Sell | No |
| Earnhardt Lisa D | 02/29/2024 | 694.00 | 84,314.00 | 118.50 | Sell | No |
| Moreland Mary K | 02/29/2024 | 676.00 | 91,260.00 | 118.50 | Sell | No |
| Salvadori Daniel Gesua Sive | 02/29/2024 | 963.00 | 125,697.00 | 118.50 | Sell | No |
| MCCOY JOHN A. JR. | 02/28/2024 | 921.00 | 19,232.00 | 120.05 | Sell | No |
| Morrone Louis H. | 02/28/2024 | 3,455.00 | 63,769.00 | 120.05 | Sell | No |
| Earnhardt Lisa D | 02/28/2024 | 7,669.00 | 85,008.00 | 120.05 | Sell | No |
| Funck, Jr. Robert E. | 02/28/2024 | 11,415.00 | 211,341.00 | 120.05 | Sell | No |
| Moreland Mary K | 02/28/2024 | 5,862.00 | 91,936.00 | 120.05 | Sell | No |
| Ford Robert B | 02/28/2024 | 31,610.00 | 220,059.00 | 120.05 | Sell | No |
Abbott Laboratories Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Abbott Laboratories | 2.08 | 1.89 | USD |
| 2022 | Abbott Laboratories | 1.92 | 1.75 | USD |
| 2021 | Abbott Laboratories | 1.82 | 1.29 | USD |
| 2020 | Abbott Laboratories | 1.53 | 1.40 | USD |
| 2019 | Abbott Laboratories | 1.32 | 1.52 | USD |
| 2018 | Abbott Laboratories | 1.16 | 1.60 | USD |
| 2017 | Abbott Laboratories | 1.08 | 1.88 | USD |
| 2016 | Abbott Laboratories | 1.05 | 2.72 | USD |
| 2015 | Abbott Laboratories | 0.98 | 2.18 | USD |
| 2014 | Abbott Laboratories | 0.90 | 2.00 | USD |
| 2013 | Abbott Laboratories | 0.64 | 1.67 | USD |
| 2012 | Abbott Laboratories | 1.67 | 2.55 | USD |
| 2011 | Abbott Laboratories | 1.92 | 3.41 | USD |
| 2010 | Abbott Laboratories | 1.76 | 3.67 | USD |
| 2009 | Abbott Laboratories | 1.60 | 2.96 | USD |
| 2008 | Abbott Laboratories | 1.44 | 2.70 | USD |
| 2007 | Abbott Laboratories | 1.30 | 2.32 | USD |
| 2006 | Abbott Laboratories | 1.18 | 2.42 | USD |
| 2005 | Abbott Laboratories | 1.10 | 2.79 | USD |
| 2004 | Abbott Laboratories | 1.04 | 2.23 | USD |
| 2003 | Abbott Laboratories | 0.98 | 2.10 | USD |
| 2002 | Abbott Laboratories | 0.94 | 2.35 | USD |
| 2001 | Abbott Laboratories | 0.84 | 1.51 | USD |
| 2000 | Abbott Laboratories | 0.76 | 1.55 | USD |
| 1999 | Abbott Laboratories | 0.68 | 1.87 | USD |
*Yield of the Respective Date
Abbott Laboratories Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.201 USD | Q3 2024 Earnings Release | 10/16/2024 |
| Earnings Report | 1.335 USD | Q4 2024 Earnings Release | 01/22/2025 |
| Earnings Report | 1.119 USD | Q1 2025 Earnings Release | 04/16/2025 |
| Earnings Report | 1.268 USD | Q2 2025 Earnings Release | 07/17/2025 |
Abbott Laboratories Past Events
| Event | Actual EPS | Info | Date |
|---|
Abbott Laboratories Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL. .
Moody’s Daily Credit Risk Score
Abbott Laboratories Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.28 |
| Vanguard Group, Inc. (Subfiler) | 9.07 |
| The Vanguard Group, Inc. | 8.99 |
| Capital Research & Management Co. (Global Investors) | 4.83 |
| State Street Corp. | 4.30 |
| Capital Research & Management Co. (International Investors) | 4.03 |
| Vanguard Total Stock Market ETF | 3.16 |
| BlackRock Fund Advisors | 2.84 |
| Vanguard 500 Index Fund | 2.57 |
| BlackRock Institutional Trust Co. NA | 2.13 |
| Geode Capital Management LLC | 1.94 |
| Wellington Management Co. LLP (Wellington Breakout) | 1.56 |
| Fidelity 500 Index Fund | 1.21 |
| American Funds Investment Company of America | 1.20 |
| SPDR S&P 500 ETF Trust | 1.17 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Abbott Laboratories Management
| Name | Job |
|---|---|
| Robert B. Ford | Chairman, President & Chief Executive Officer |
| Gene Huang | Chief Economist & Vice President |
| Philip P. Boudreau | Chief Financial Officer & Senior VP-Finance |
| Melissa Brotz | Chief Marketing & Communications Officer |
| Andrea F. Wainer | Executive VP-Rapid & Molecular Diagnostics |
| Mary K. Moreland | Executive Vice President-Human Resources |
| Daniel Gesua Sive Salvadori | Executive Vice President-Nutritional Products |
| John M. Capek | Executive Vice President-Ventures |
| Joanne T. Beck | Global Pharmaceutical Operations |
| Lisa D. Earnhardt | Group President-Medical Devices & Executive VP |
| Sally E. Blount | Independent Director |
| John G. Stratton | Independent Director |
| Michael F. Roman | Independent Director |
| Daniel J. Starks | Independent Director |
| Nancy McKinstry | Independent Director |
| Claire L. Babineaux-Fontenot | Independent Director |
| Michael G. O'Grady | Independent Director |
| Darren W. McDew | Independent Director |
| Michelle A. Kumbier | Independent Director |
| Paola Gonzalez | Independent Director |
| Robert J. Alpern | Independent Director |
| Jim Leffelman | Manager-Expense Reporting |
| Karen Wong Chayavirabood | Regional Director-Asia |
| Hubert L. Allen | Secretary, Executive VP & General Counsel |
| Scott J. House | Senior VP-Regulatory & Engineering Services |
| Randel William Woodgrift | Senior Vice President-Cardiac Rhythm Management |
| Scott Leinenweber | Senior Vice President-Licensing & Acquisitions |
| Alison Davies | Treasurer & Vice President |
| Kathryn S. Collins | Vice President-Commercial Legal Operations |
| John A. McCoy | Vice President-Finance & Controller |